JANX

Janux Therapeutics, Inc.

Fundamental data last updated:November 18, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

02/25/2027

Business Summary

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.

 


VALUATION

P/E

-7.18

Market Cap ($M USD)

$703.30M

Forward P/E

-4.75

PEG

0.43

PRICE TO SALES

30.20

PRICE TO BOOK

0.80

EV / EBITDA

-6.96

5-Year Average P/E

Free Cash Flow Yield

-7.70%

DCF Value

$-3.15

Graham Number

N/A

Price to FCF

-12.99

EV to FCF

-12.59

Earnings Yield

-13.77%

FCF Yield

-7.70%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$1.58

Next Year EPS Growth Estimate

-$1.65

Next Year Revenue Growth Estimate

$27.92M

Return on Equity (ROE)

-10.68%

FREE CASH FLOW

Operating Margin

-599.26%

Debt-to-Equity

0.02

Piotroski F-Score

2

Altman Z-Score

6.51

Return on Invested Capital (ROIC)

-14.97%

Current Ratio

17.69

Quick Ratio

17.69

Net Debt to EBITDA

0.22

Interest Coverage

0.00

Gross Profit margin

100.00%

FCF PER SHARE

$-0.86

REVENUE PER SHARE

$0.37

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing Janux Therapeutics, Inc. significantly. Despite a negative DCF value, the stock’s price has traded well above this metric, suggesting overvaluation. The Forward P/E and Earnings Yield are deeply negative, indicating a lack of profitability in the near term. However, the Altman Z-score of 6.16 suggests financial stability, hinting at a low risk of bankruptcy. This paradox of safety amidst poor earnings performance creates a complex investment narrative.

AI Exposure / Tech Reliance

Positioned within the biotechnology sector, Janux Therapeutics is inherently aligned with cutting-edge technological advancements. The industry's rapid adoption of AI for drug discovery and personalized medicine offers a fertile ground for growth. However, the company's ability to capitalize on these shifts remains speculative given its current financial metrics.

The Bull Case

For the optimistic investor, Janux presents an intriguing opportunity. The exceptionally low PEG Forward ratio of 0.07 suggests potential undervaluation relative to its growth prospects. Despite negative ROIC and FCF Yield, the company's robust Altman Z-score and high Current Ratio indicate strong financial health. These metrics suggest that Janux could leverage its capital efficiently once it achieves profitability, offering a long-term growth story.

The Bear Case

Janux's structural weaknesses are glaring. The Price/Sales ratio of nearly 40 and negative EV to EBITDA highlight a severe overvaluation and lack of earnings. The company's negative EPS and operating margin underscore its struggle to generate profit. Additionally, trading close to its 52-week high suggests technical overextension, making it a risky bet for those wary of inflated valuations.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$34.75

Institutional Ownership %

1-Year Beta

2.39

Insider Buying % (6 Mo)

Distance to 52-Week High

207.44%

Distance to 52-Week Low

0.39%

EARNINGS SURPRISE %

28.19%

50-DAY SMA

$17.13

200-DAY SMA

$15.38

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.